Immunosuppression associated with chronic inflammation in the tumor microenvironment

Carcinogenesis

Volumn 36, Issue 10, 2015, Pages 1085-1093

  Wang, Dingzhi ^a   Du Bois, Raymond N ^a,b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE MARROW CELL; CANCER CELL; CARCINOGENESIS; CHRONIC INFLAMMATION; DENDRITIC CELL; GASTRIC MUCOSA; GRANULOCYTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE FLORA; MACROPHAGE; MESENTERY LYMPH NODE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; CHRONIC DISEASE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INFLAMMATION; MELANOMA; PATHOLOGY; T LYMPHOCYTE;

CHRONIC DISEASE; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; INFLAMMATION; MELANOMA; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84943737064     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv123     Document Type: Article

References (125)

1. Lakatos, P.L. et al. (2008) Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J. Gastroenterol., 14, 3937-3947.
2. Kuper, H. et al. (2000) Infections as a major preventable cause of human cancer. J. Intern. Med., 248, 171-183.
3. Algra, A.M. et al. (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol., 13, 518-527.
4. Harris, R.E. (2009) Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology, 17, 55-67.
5. Rothwell, P.M. et al. (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet, 379, 1602-1612.
6. Rothwell, P.M. et al. (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet, 379, 1591-1601.
7. Neuman, M.G. (2007) Immune dysfunction in inflammatory bowel disease. Transl. Res., 149, 173-186.
8. Sands, B.E. (2007) Inflammatory bowel disease: past, present, and future. J. Gastroenterol., 42, 16-25.
9. Strober, W. et al. (2007) The fundamental basis of inflammatory bowel disease. J. Clin. Invest., 117, 514-521.
10. Noonan, D.M. et al. (2008) Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev., 27, 31-40.
11. Greten, F.R. et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118, 285-296.
12. Grivennikov, S. et al. (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell, 15, 103-113.
13. Wang, K. et al. (2013). Implications of anti-cytokine therapy in colorectal cancer and autoimmune diseases. Ann. Rheum. Dis., 72 (suppl. 2), ii100-ii103.
14. Chung, H.W. et al. (2014). Role of the tumor microenvironment in the pathogenesis of gastric carcinoma. World J. Gastroenterol., 20, 1667-1680.
15. Wang, D. et al. (2014) Peroxisome proliferator-activated receptor d promotes colonic inflammation and tumor growth. Proc. Natl Acad. Sci. USA, 111, 7084-7089.
16. Wang, D. et al. (2009) The role of chemokines in intestinal inflammation and cancer. Curr. Opin. Pharmacol., 9, 688-696.
17. Andres, P.G. et al. (2000) Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfatemediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. J. Immunol., 164, 6303-6312.
18. Katoh, H. et al. (2013) CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell, 24, 631-644.
19. Khan, W.I. et al. (2006) Critical role of MCP-1 in the pathogenesis of experimental colitis in the context of immune and enterochromaffin cells. Am. J. Physiol. Gastrointest. Liver Physiol., 291, G803-G811.
20. Tokuyama, H. et al. (2005) The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int. Immunol., 17, 1023-1034.
21. Horiike, S. et al. (2005) Accumulation of 8-nitroguanine in the liver of patients with chronic hepatitis C. J. Hepatol., 43, 403-410.
22. Murata, M. et al. (2012) Role of nitrative and oxidative DNA damage in inflammation-related carcinogenesis. J. Biomed. Biotechnol., 2012, 623019.
23. Rachmilewitz, D. et al. (1995) Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Gut, 36, 718-723.
24. Rieder, G. et al. (2003) Up-regulation of inducible nitric oxide synthase in Helicobacter pylori-associated gastritis may represent an increased risk factor to develop gastric carcinoma of the intestinal type. Int. J. Med. Microbiol., 293, 403-412.
25. Hussain, S.P. et al. (2000) Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res., 60, 3333-3337.
26. Gasche, J.A. et al. (2011) Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells. Int. J. Cancer, 129, 1053-1063.
27. Xia, D. et al. (2012) Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat. Med., 18, 224-226.
28. Schwitalla, S. et al. (2013) Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell, 152, 25-38.
29. Kanterman, J. et al. (2012) New insights into chronic inflammationinduced immunosuppression. Semin. Cancer Biol., 22, 307-318.
30. Haile, L.A. et al. (2008) Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology, 135, 871-881, 881.e1-881.e5.
31. Poh, T.W. et al. (2013) Downregulation of hematopoietic MUC1 during experimental colitis increases tumor-promoting myeloid-derived suppressor cells. Clin. Cancer Res., 19, 5039-5052.
32. Ostrand-Rosenberg, S. et al. (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol., 182, 4499-4506.
33. Wang, D. et al. (2013) An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J., 19, 502-510.
34. Asfaha, S. et al. (2013) Mice that express human interleukin-8 have increased mobilization of immature myeloid cells, which exacerbates inflammation and accelerates colon carcinogenesis. Gastroenterology, 144, 155-166.
35. Tu, S. et al. (2008) Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell, 14, 408-419.
36. Izcue, A. et al. (2008) Special regulatory T-cell review: Regulatory T cells and the intestinal tract-patrolling the frontier. Immunology, 123, 6-10.
37. Eastaff-Leung, N. et al. (2010) Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J. Clin. Immunol., 30, 80-89.
38. Kandulski, A. et al. (2010) Role of regulatory T-cells in H. pylori-induced gastritis and gastric cancer. Anticancer Res., 30, 1093-1103.
39. Uhlig, H.H. et al. (2006) Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J. Immunol., 177, 5852-5860.
40. Nguyen, T.L. et al. (2014) In vitro induced regulatory T cells are unique from endogenous regulatory T cells and effective at suppressing late stages of ongoing autoimmunity. PLoS One, 9, e104698.
41. Rad, R. et al. (2006) CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology, 131, 525-537.
42. Gounaris, E. et al. (2009) T-regulatory cells shift from a protective antiinflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res., 69, 5490-5497.
43. Hovhannisyan, Z. et al. (2011) Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology, 140, 957-965.
44. Kryczek, I. et al. (2011) IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. J. Immunol., 186, 4388-4395.
45. Li, L. et al. (2010) IL-1ß-mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into IL-17-producing cells. J. Immunol., 185, 4148-4153.
46. Raffin, C. et al. (2011) Ex vivo IL-1 receptor type I expression in human CD4+ T cells identifies an early intermediate in the differentiation of Th17 from FOXP3+ naive regulatory T cells. J. Immunol., 187, 5196-5202.
47. Li, L. et al. (2013) The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer. Clin. Immunol., 148, 246-253.
48. Pastille, E. et al. (2014) Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancer. Cancer Res., 74, 4258-4269.
49. Kido, M. et al. (2008) Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology, 135, 1333-1343.
50. Nishiura, H. et al. (2013) Interleukin-21 and tumor necrosis factor-a are critical for the development of autoimmune gastritis in mice. J. Gastroenterol. Hepatol., 28, 982-991.
51. Reynoso, E.D. et al. (2009) Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J. Immunol., 182, 2102-2112.
52. Kinter, A.L. et al. (2008) The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J. Immunol., 181, 6738-6746.
53. Nakazawa, A. et al. (2004) The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology, 126, 1347-1357.
54. Wu, Y.Y. et al. (2010) Increased programmed death-ligand-1 expression in human gastric epithelial cells in Helicobacter pylori infection. Clin. Exp. Immunol., 161, 551-559.
55. Berman, D. et al. (2010) Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun., 10, 11.
56. Anderson, K.M. et al. (2006) Induction of CTLA-4-mediated anergy contributes to persistent colonization in the murine model of gastric Helicobacter pylori infection. J. Immunol., 176, 5306-5313.
57. Watanabe, K. et al. (2004) CTLA-4 blockade inhibits induction of Helicobacter pylori-associated gastritis in mice. Clin. Exp. Immunol., 135, 29-34.
58. Read, S. et al. (2000) Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med., 192, 295-302.
59. Takahashi, T. et al. (2000) Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med., 192, 303-310.
60. Wing, K. et al. (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science, 322, 271-275.
61. Kim, G. et al. (2008) Spontaneous colitis occurrence in transgenic mice with altered B7-mediated costimulation. J. Immunol., 181, 5278-5288.
62. Diaz-Montero, C.M. et al. (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother., 58, 49-59.
63. Duffy, A. et al. (2013) Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. Cancer Immunol. Immunother., 62, 299-307.
64. Gabitass, R.F. et al. (2011) Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol. Immunother., 60, 1419-1430.
65. Mandruzzato, S. et al. (2009) IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J. Immunol., 182, 6562-6568.
66. Sun, H.L. et al. (2012) Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J. Gastroenterol., 18, 3303-3309.
67. Wang, L. et al. (2013) Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J. Immunol., 190, 794-804.
68. Zhang, B. et al. (2013) Circulating and tumor-infiltrating myeloidderived suppressor cells in patients with colorectal carcinoma. PLoS One, 8, e57114.
69. Gabrilovich, D.I. et al. (2012) Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol., 12, 253-268.
70. Cui, T.X. et al. (2013) Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity, 39, 611-621.
71. Di Mitri, D. et al. (2014) Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature, 515, 134-137.
72. Yang, L. et al. (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell, 13, 23-35.
73. Acharyya, S. et al. (2012) A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell, 150, 165-178.
74. Cheng, P. et al. (2008) Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med., 205, 2235-2249.
75. Gabrilovich, D.I. et al. (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol., 9, 162-174.
76. Yu, J. et al. (2014) Noncanonical NF-kappaB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J. Immunol., 193, 2574-2586.
77. Li, L. et al. (2014) MicroRNA-155 and MicroRNA-21 promote the expansion of functional myeloid-derived suppressor cells. J. Immunol., 192, 1034-1043.
78. Sinha, P. et al. (2007) Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res., 67, 4507-4513.
79. Obermajer, N. et al. (2011) Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood, 118, 5498-5505.
80. Rodriguez, P.C. et al. (2005) Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med., 202, 931-939.
81. Veltman, J.D. et al. (2010) COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer, 10, 464.
82. Mao, Y. et al. (2014) Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin. Cancer Res., 20, 4096-4106.
83. Fujita, M. et al. (2011) COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res., 71, 2664-2674.
84. Ichihara, F. et al. (2003) Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res., 9, 4404-4408.
85. Mizukami, Y. et al. (2008) CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int. J. Cancer, 122, 2286-2293.
86. Wolf, A.M. et al. (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res., 9, 606-612.
87. Curiel, T.J. et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med., 10, 942-949.
88. Kono, K. et al. (2006) CD4(+)CD25 high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol. Immunother., 55, 1064-1071.
89. Antony, P.A. et al. (2005) CD8+ T cell immunity against a tumor/selfantigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol., 174, 2591-2601.
90. Casares, N. et al. (2003) CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J. Immunol., 171, 5931-5939.
91. Onizuka, S. et al. (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res., 59, 3128-3133.
92. Shimizu, J. et al. (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol., 163, 5211-5218.
93. Turk, M.J. et al. (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med., 200, 771-782.
94. Gobert, M. et al. (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res., 69, 2000-2009.
95. Pere, H. et al. (2011) A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood, 118, 4853-4862.
96. Chang, L.Y. et al. (2012) Tumor-derived chemokine CCL5 enhances TGF-ß-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res., 72, 1092-1102.
97. Tan, W. et al. (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature, 470, 548-553.
98. Ghiringhelli, F. et al. (2005) Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med., 202, 919-929.
99. Liu, V.C. et al. (2007) Tumor evasion of the immune system by converting CD4+CD25-T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J. Immunol., 178, 2883-2892.
100. Ahmadzadeh, M. et al. (2006) IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood, 107, 2409-2414.
101. Jensen, H.K. et al. (2009) Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin. Cancer Res., 15, 1052-1058.
102. Terme, M. et al. (2013) VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res., 73, 539-549.
103. Muthuswamy, R. et al. (2008) Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res., 68, 5972-5978.
104. Baratelli, F. et al. (2005) Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J. Immunol., 175, 1483-1490.
105. Sharma, S. et al. (2005) Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res., 65, 5211-5220.
106. Nakanishi, M. et al. (2011) Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity. Cancer Prev. Res. (Phila.), 4, 1198-1208.
107. Soontrapa, K. et al. (2011) Prostaglandin E2-prostaglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression. Proc. Natl Acad. Sci. USA, 108, 6668-6673.
108. Barber, D.L. et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 439, 682-687.
109. Ahmadzadeh, M. et al. (2009) Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood, 114, 1537-1544.
110. Fourcade, J. et al. (2009) PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J. Immunol., 182, 5240-5249.
111. Mumprecht, S. et al. (2009) Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood, 114, 1528-1536.
112. Dong, H. et al. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med., 8, 793-800.
113. Strome, S.E. et al. (2003) B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res., 63, 6501-6505.
114. Zhu, J. et al. (2014) MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum. Immunol., 75, 348-353.
115. Hamanishi, J. et al. (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl Acad. Sci. USA, 104, 3360-3365.
116. Ohigashi, Y. et al. (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res., 11, 2947-2953.
117. Song, M. et al. (2013) PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One, 8, e65821.
118. Thompson, R.H. et al. (2005) B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology, 66 (suppl. 5), 10-14.
119. Cao, Y. et al. (2011) B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin. Cancer Res., 71, 1235-1243.
120. Kyi, C. et al. (2014) Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett., 588, 368-376.
121. Akbay, E.A. et al. (2013) Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov., 3, 1355-1363.
122. Azuma, K. et al. (2014) Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann. Oncol., 25, 1935-1940.
123. Parsa, A.T. et al. (2007) Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med., 13, 84-88.
124. Qian, Y. et al. (2008) TLR4 signaling induces B7-H1 expression through MAPK pathways in bladder cancer cells. Cancer Invest., 26, 816-821.
125. Highfill, S.L. et al. (2014) Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med., 6, 237ra67.